ProFound Therapeutics Enters Four-Year Collaboration with Novartis to Develop Cardiovascular Treatments
Friday, June 27, 2025
ProFound Therapeutics has entered a strategic four-year collaboration with Novartis to discover and develop new treatments for cardiovascular disease. The partnership will make use of ProFound’s proprietary ProFoundry™ Platform to identify novel proteins and therapeutic targets within the expanded human proteome.
This collaboration combines ProFound’s ability to uncover previously unexplored proteins with Novartis’ extensive experience in cardiovascular drug development. The joint effort aims to deliver innovative therapies for a growing global population affected by heart-related conditions.
The ProFoundry Platform integrates complex biological datasets with advanced computational methods to discover and validate new protein-based drug candidates and targets. By working together, the two companies hope to go beyond traditional methods of target discovery and tap into areas of human biology that remain under-researched.
As part of the agreement, ProFound will receive $25 million in upfront and near-term milestone payments. The collaboration also includes potential milestone payments of up to $750 million per selected target, in addition to tiered royalties on future sales.
This partnership reflects a shared commitment to advancing research and bringing forward next-generation cardiovascular treatments through the exploration of novel biological mechanisms.
Source: globenewswire.com
